Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Tokyo, Japan and Cambridge, UK, December 20, 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565), previously referred to as Sosei Group or Sosei Heptares, has revealed that Chris Cargill, the President and CEO, will speak at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:00 p.m. PST.
Investors, analysts, media representatives, and the public are welcome to tune in to a live audio broadcast of the presentation at this link.
The investor section of the Company's website will provide access to the presentation slides.
About Nxera Pharma Nxera Pharma, previously known as Sosei Heptares, is a biopharmaceutical company driven by innovative technology. Its aim is to develop new specialized treatments that enhance the quality of life for patients who have unmet medical needs, both in Japan and around the world.
Alongside a range of products being launched in Japan, we are developing a robust pipeline of more than 30 active projects, from early discovery to late clinical stages, both internally and in collaboration with top pharmaceutical and biotech firms. This pipeline aims to tackle significant unmet medical needs in rapidly expanding fields such as neurology, gastrointestinal conditions, immunology, metabolic disorders, and rare diseases. We utilize our innovative NxWave™ platform, which specializes in structure-based drug discovery targeting GPCRs, to create a reliable stream of leading or groundbreaking treatment candidates.
Nxera has a workforce of more than 350 skilled individuals situated in important cities like Tokyo and Osaka in Japan, London and Cambridge in the UK, Basel in Switzerland, and Seoul in South Korea. The company is publicly traded on the Tokyo Stock Exchange under the ticker symbol 4565.
For additional details, feel free to check out our website at www.nxera.life. You can also find us on LinkedIn at @NxeraPharma, on X at @NxeraPharma, and on YouTube at @NxeraPharma.
Nxera – Media and Investor Relations Kentaro Tahara, Vice President of Investor Relations and Corporate Strategy Shinichiro Nishishita, Vice President of Investor Relations, Head of Regulatory Disclosures Maya Bennison, Communications Manager +81 (0)3 5210 3399 | +44 (0)1223 949390 | [email protected]
MEDiSTRAVA (International Media Contact) Mark Swallow, Frazer Hall, Erica Hollingsworth Phone: +44 (0)203 928 6900 | Email: [email protected]
**Statements About Future Expectations** This announcement includes statements about future expectations, particularly regarding the discovery, development, and marketing of products. Several risks could lead to significant differences between Nxera Pharma Group's actual outcomes and those indicated in the forward-looking statements. These risks include negative results in clinical trials, the inability to secure patent protection for innovations, restrictions related to patents held by others, reliance on partners for the development and marketing of products and services, challenges in acquiring regulatory approval for products and services stemming from development efforts, a need for substantial funding for research and development as well as for commercial expansion, and competitive actions. Because of these factors, potential investors should be cautious in their reliance on any forecasts. We do not intend or feel obligated to update or change any forward-looking statements based on new information, future occurrences, or other reasons.
